These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8242638)
21. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696 [TBL] [Abstract][Full Text] [Related]
22. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. Barbareschi M; Girlando S; Mauri FA; Arrigoni G; Laurino L; Dalla Palma P; Doglioni C J Pathol; 1992 Apr; 166(4):343-50. PubMed ID: 1355531 [TBL] [Abstract][Full Text] [Related]
23. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996 [TBL] [Abstract][Full Text] [Related]
24. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history. Bennett WP; von Brevern MC; Zhu SM; Bartsch H; Muehlbauer KR; Hollstein MC Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):963-6. PubMed ID: 9367071 [TBL] [Abstract][Full Text] [Related]
25. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113 [TBL] [Abstract][Full Text] [Related]
26. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762 [TBL] [Abstract][Full Text] [Related]
27. p53 mutation is infrequent in clear cell carcinoma of the ovary. Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858 [TBL] [Abstract][Full Text] [Related]
28. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Kidd M; Eick G; Shapiro MD; Camp RL; Mane SM; Modlin IM Cancer; 2005 Jan; 103(2):229-36. PubMed ID: 15599934 [TBL] [Abstract][Full Text] [Related]
29. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246 [TBL] [Abstract][Full Text] [Related]
30. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer. Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268 [TBL] [Abstract][Full Text] [Related]
31. Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors. Naranjo Gómez JM; Bernal JF; Arranz PG; Fernández SL; Roman JJ Arch Pathol Lab Med; 2014 Jul; 138(7):936-42. PubMed ID: 24978920 [TBL] [Abstract][Full Text] [Related]
32. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Cripps KJ; Purdie CA; Carder PJ; White S; Komine K; Bird CC; Wyllie AH Oncogene; 1994 Sep; 9(9):2739-43. PubMed ID: 8058340 [TBL] [Abstract][Full Text] [Related]
33. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Swarts DR; Ramaekers FC; Speel EJ Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738 [TBL] [Abstract][Full Text] [Related]
34. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Marchetti A; Felicioni L; Pelosi G; Del Grammastro M; Fumagalli C; Sciarrotta M; Malatesta S; Chella A; Barassi F; Mucilli F; Camplese P; D'Antuono T; Sacco R; Buttitta F Hum Mutat; 2008 May; 29(5):609-16. PubMed ID: 18293376 [TBL] [Abstract][Full Text] [Related]
35. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Wistuba II; Thomas B; Behrens C; Onuki N; Lindberg G; Albores-Saavedra J; Gazdar AF Gynecol Oncol; 1999 Jan; 72(1):3-9. PubMed ID: 9889022 [TBL] [Abstract][Full Text] [Related]
36. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676 [TBL] [Abstract][Full Text] [Related]
37. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838 [TBL] [Abstract][Full Text] [Related]
38. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192 [TBL] [Abstract][Full Text] [Related]
39. Analysis of p53 abnormalities in endoscopic gastric biopsies. Imatani A; Sasano H; Asaki S; Toyota T; Saito M; Masuda T; Nagura H Anticancer Res; 1996; 16(4A):2049-56. PubMed ID: 8712741 [TBL] [Abstract][Full Text] [Related]
40. Carcinomas of the lung with neuroendocrine differentiation. Carter D; Yesner R Semin Diagn Pathol; 1985 Nov; 2(4):235-54. PubMed ID: 3039628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]